These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8162073)

  • 1. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types.
    Bianchi AB; Hara T; Ramesh V; Gao J; Klein-Szanto AJ; Morin F; Menon AG; Trofatter JA; Gusella JF; Seizinger BR
    Nat Genet; 1994 Feb; 6(2):185-92. PubMed ID: 8162073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cloning and characterization of alternatively spliced transcripts of the mouse neurofibromatosis 2 gene.
    Hara T; Bianchi AB; Seizinger BR; Kley N
    Cancer Res; 1994 Jan; 54(2):330-5. PubMed ID: 7506121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?
    Kley N; Seizinger BR
    Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.
    Kley N; Whaley J; Seizinger BR
    Glia; 1995 Nov; 15(3):297-307. PubMed ID: 8586465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neurofibromatosis type 2 (NF2)].
    Araki N; Takeshima H; Saya H
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.
    Koga H; Araki N; Takeshima H; Nishi T; Hirota T; Kimura Y; Nakao M; Saya H
    Oncogene; 1998 Aug; 17(7):801-10. PubMed ID: 9779996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and distribution of NF2 mutations in schwannomas.
    Jacoby LB; MacCollin M; Barone R; Ramesh V; Gusella JF
    Genes Chromosomes Cancer; 1996 Sep; 17(1):45-55. PubMed ID: 8889506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of neurofibromatosis 2 transcript and gene product during mouse fetal development.
    Huynh DP; Tran TM; Nechiporuk T; Pulst SM
    Cell Growth Differ; 1996 Nov; 7(11):1551-61. PubMed ID: 8930405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofibromatosis type 2 protein co-localizes with elements of the cytoskeleton.
    den Bakker MA; Tascilar M; Riegman PH; Hekman AC; Boersma W; Janssen PJ; de Jong TA; Hendriks W; van der Kwast TH; Zwarthoff EC
    Am J Pathol; 1995 Nov; 147(5):1339-49. PubMed ID: 7485397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin.
    Scoles DR; Huynh DP; Morcos PA; Coulsell ER; Robinson NG; Tamanoi F; Pulst SM
    Nat Genet; 1998 Apr; 18(4):354-9. PubMed ID: 9537418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.
    Rouleau GA; Merel P; Lutchman M; Sanson M; Zucman J; Marineau C; Hoang-Xuan K; Demczuk S; Desmaze C; Plougastel B
    Nature; 1993 Jun; 363(6429):515-21. PubMed ID: 8379998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the neurofibromatosis 2 gene in human breast and hepatocellular carcinomas.
    Kanai Y; Tsuda H; Oda T; Sakamoto M; Hirohashi S
    Jpn J Clin Oncol; 1995 Feb; 25(1):1-4. PubMed ID: 7877257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interdomain binding mediates tumor growth suppression by the NF2 gene product.
    Sherman L; Xu HM; Geist RT; Saporito-Irwin S; Howells N; Ponta H; Herrlich P; Gutmann DH
    Oncogene; 1997 Nov; 15(20):2505-9. PubMed ID: 9395247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A point mutation associated with a severe phenotype of neurofibromatosis 2.
    MacCollin M; Braverman N; Viskochil D; Ruttledge M; Davis K; Ojemann R; Gusella J; Parry DM
    Ann Neurol; 1996 Sep; 40(3):440-5. PubMed ID: 8797533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of genetic and epigenetic changes in meningiomas without NF2 loss.
    van Tilborg AA; Morolli B; Giphart-Gassler M; de Vries A; van Geenen DA; Lurkin I; Kros JM; Zwarthoff EC
    J Pathol; 2006 Mar; 208(4):564-73. PubMed ID: 16353169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development and establishment of a yeast-based stop codon assay for detection of NF2 gene premature-terminating mutations].
    Kobayashi H
    Hokkaido Igaku Zasshi; 1999 Sep; 74(5):377-86. PubMed ID: 10495852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
    Pollock PM; Pearson JV; Hayward NK
    Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells.
    Lutchman M; Rouleau GA
    Cancer Res; 1995 Jun; 55(11):2270-4. PubMed ID: 7757975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new tumor suppressor gene responsible for type 2 neurofibromatosis is inactivated in neurinoma and meningioma].
    Sanson M
    Rev Neurol (Paris); 1996 Jan; 152(1):1-10. PubMed ID: 8729390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular-genetic aspects of neurofibromatosis].
    Hulsebos TJ
    Ned Tijdschr Geneeskd; 1997 Mar; 141(13):620-3. PubMed ID: 9190537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.